Nrc Health earnings release, July 28, 2026
NRC HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS
Second quarter TRCV* increased 11% year-over-year to $151.9 million
LINCOLN, Nebraska, July 28, 2026 — NRC Health (NASDAQ: NRC), a leader in healthcare experience improvement solutions, today announced results for the second quarter 2026.
"Our second quarter was a success on many fronts, including double-digit TRCV growth over the prior year, strong go-to-market and solutions delivery execution, continued commercialization of our product innovations, and the strongest bookings performance for The Governance Institute in seven years, positioning us well for a strong second half of 2026,” said Trent Green, CEO of NRC Health. “As healthcare organizations increasingly seek partners who can help improve experience outcomes, strengthen governance, and build enduring brand value, we believe NRC Health is uniquely differentiated through our three connected strengths: delivering continuous consumer and patient insights, providing trusted partnership and strategic engagement with healthcare leaders, and enabling actions that lead to improved outcomes.”
Second Quarter 2026 Highlights
* These financial measures are defined below under the headings
“
Non-GAAP Financial Measures” and
“
Total Recurring Contract Value.”
Reconciliations of the non-GAAP measures to their most closely comparable GAAP measures are included in the tables in this release.
Dividend Declaration
The Company’s Board of Directors on July 15, 2026, declared a quarterly cash dividend of $0.16 per share. The dividend will be payable on Friday, October 9, 2026, to shareholders of record as of the close of business on Friday, September 25, 2026.
© NRC Health
NRC Health Announces First Quarter 2026 Results
Page 2
July 28, 2026
Earnings Call Information
The company will be hosting a conference call to discuss the financial results on Tuesday, July 28, 2026, at 4:30 p.m. ET. A live webcast and replay of the call will be available on the NRC Health Investor Relations website at nrchealth.com/investor-relations.
About NRC Health
For more than 45 years, NRC Health (NASDAQ: NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health’s commitment to Human Understanding® helps leading healthcare systems get to know the patients, families, consumers, employees, and communities they serve on a human level. Guided by its uniquely empathic heritage, human-centered approach, unmatched national market research, and emphasis on consumer preferences, NRC Health is transforming the healthcare experience, creating strong outcomes across the healthcare journey. For more information, email info@nrchealth.com, or visit www.nrchealth.com.
Total Recurring Contract Value
Total Recurring Contract Value, or TRCV, is viewed by management as a leading indicator of our future revenue trends. It represents the total annualized contract value under customer contracts that are in effect or contractually committed as of the most recent quarter-end, based on contractual pricing and term provisions, and expected to be in force over the subsequent 12 months. TRCV is an operating metric and is not a measure of revenue recognized under U.S. GAAP.
Non-GAAP Financial Measures
In addition to consolidated GAAP financial measures, NRC Health reviews various non-GAAP financial measures that management believes to be important in the evaluation of its operating results and performance, including “Adjusted Net Income,” “Adjusted Earnings per Share,” “Adjusted EBITDA,” “Adjusted EBITDA Margin,” “Free Cash Flow,” and “Free Cash Flow Margin.” Reconciliations of GAAP to non-GAAP financial information are provided later in this release.
NRC Health believes Adjusted Net Income, Adjusted Earnings per Share, Adjusted EBITDA, and Adjusted EBITDA Margin are helpful supplemental measures to assist management and investors in evaluating the Company’s operating results as (i) they exclude certain items that are unusual in nature or whose fluctuation from period to period do not necessarily correspond to changes in the operations of NRC Health’s business, and (ii) the exclusion of non-cash stock compensation is useful for investors applying certain valuation metrics and is consistent with the leverage ratio for our credit facility.
Adjusted Net Income represents net income adjusted to add back management transition costs and non-cash stock compensation and the related tax. The income tax effect on non-GAAP adjustments is calculated by applying the Company's blended federal and state statutory rate to the deductible portion of each adjustment; amounts nondeductible under Section 162(m) of the Internal Revenue Code receive no tax effect. Adjusted EBITDA represents net income before interest, taxes, depreciation, amortization, management transition costs, and non-cash stock compensation items. Adjusted EBITDA Margin represents Adjusted EBITDA divided by our revenue.
© NRC Health
NRC Health Announces First Quarter 2026 Results
Page 3
July 28, 2026... (truncated)in connection with amendments to their 2025 equity awards, as previously disclosed, and approximately $270,000 of severance costs incurred in connection with team restructurings implemented by newly appointed executives.
NRC Health considers Free Cash Flow to be a measure that provides useful information to management and investors about our liquidity. Free Cash Flow does not represent residual cash flow available for discretionary expenditures. We define Free Cash Flow as net cash provided by operating activities less capital expenditures. Free Cash Flow Margin represents Free Cash Flow divided by our revenue.
There is no comprehensive, authoritative guidance for the presentation of such non-GAAP information, which is only meant to supplement GAAP results by providing additional information that management utilizes to assess performance.
Financial statements
Income Statement
Three months ended June 30, — (In thousands except per share data, unaudited)
| Three months ended June 30, – 2026 | Three months ended June 30, – 2025 | Six months ended June 30, – 2026 | Six months ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Revenue | 35,392 | 34,038 | 70,195 | 67,588 | |
| Operating expenses: | Direct | 13,564 | 12,974 | 27,210 | 26,031 |
| Operating expenses: | Selling, general, and administrative | 22,945 | 17,734 | 36,364 | 28,089 |
| Operating expenses: | Depreciation and amortization | 2,121 | 1,742 | 4,290 | 3,284 |
| Operating expenses: | Total operating expenses | 38,630 | 32,450 | 67,864 | 57,404 |
| Operating expenses: | Operating income (loss) | -3,238 | 1,588 | 2,331 | 10,184 |
| Other income (expense): | Interest income | 20 | 21 | 55 | 41 |
| Other income (expense): | Interest expense | -1,321 | -1,032 | -2,576 | -1,932 |
| Other income (expense): | Other, net | 2 | 4 | 32 | 11 |
| Other income (expense): | Total other expense | -1,299 | -1,007 | -2,489 | -1,880 |
| Other income (expense): | Income (loss) before income taxes | -4,537 | 581 | -158 | 8,304 |
| Other income (expense): | Provision for income taxes | -1,254 | 687 | -97 | 2,623 |
| Other income (expense): | Net income (loss) | -3,283 | -106 | -61 | 5,681 |
| Earnings (loss) per share of common stock: | Basic | -0.15 | -0.01 | -0.01 | 0.25 |
| Earnings (loss) per share of common stock: | Diluted | -0.15 | -0.01 | -0.01 | 0.25 |
| Weighted average shares and share equivalents outstanding: | Basic | 22,009 | 22,658 | 21,905 | 22,814 |
| Weighted average shares and share equivalents outstanding: | Diluted | 22,009 | 22,658 | 21,905 | 22,820 |
Income Statement
Three months ended June 30, — Adjusted Net Income and Adjusted Earnings per Share (in thousands)
| Three months ended June 30, – 2026 | Three months ended June 30, – 2025 | Six months ended June 30, – 2026 | Six months ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Net income (loss) | -3,283 | -106 | -61 | 5,681 | |
| Add back: | Management transition costs1 | 3,160 | 6,640 | 3,160 | 6,640 |
| Add back: | Tax on management transition costs 2 | -180 | -468 | -180 | -468 |
| Add back: | Non-cash stock compensation | 7,371 | 307 | 8,979 | 478 |
| Add back: | Tax on non-cash stock compensation 2 | -210 | 22 | -470 | -21 |
| Add back: | Adjusted net income | 6,858 | 6,395 | 11,428 | 12,310 |
| Add back: | Earnings (loss) per share of common stock, diluted | -0.15 | -0.01 | -0.01 | 0.25 |
| Add back: | Weighted average shares and share equivalents outstanding, diluted | 22,009 | 22,658 | 21,905 | 22,820 |
| Add back: | Adjusted earnings per share of common stock, diluted | 0.31 | 0.28 | 0.52 | 0.54 |
| Add back: | Adjusted weighted average shares and share equivalents outstanding, diluted | 22,113 | 22,661 | 22,049 | 22,820 |
Income Statement
Three months ended June 30, — Adjusted EBITDA and Adjusted EBITDA Margin
| Three months ended June 30, – 2026 | Three months ended June 30, – 2025 | Six months ended June 30, – 2026 | Six months ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Net income (loss) | -3,283 | -106 | -61 | 5,681 | |
| Add back: | Depreciation and amortization | 2,121 | 1,742 | 4,290 | 3,284 |
| Add back: | Interest expense | 1,321 | 1,032 | 2,576 | 1,931 |
| Add back: | Income taxes | -1,254 | 687 | -97 | 2,623 |
| Add back: | Management transition costs1 | 3,160 | 6,640 | 3,160 | 6,640 |
| Add back: | Non-cash stock compensation | 7,371 | 307 | 8,979 | 478 |
| Add back: | Adjusted EBITDA | 9,436 | 10,302 | 18,847 | 20,637 |
| Add back: | Net income (loss) margin | -9.0% | 8 | ||
| Add back: | Adjusted EBITDA margin | 27.0% | 30.0% | 27.0% | 31 |
Balance Sheet
June 30, 2026 — (Dollars in thousands except share amounts and par value)
| June 30, 2026 – (unaudited) | December 31, 2025 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 3,327 | 4,139 |
| Current assets: | Accounts receivable, net | 9,324 | 11,108 |
| Current assets: | Other current assets | 10,155 | 4,962 |
| Current assets: | Total current assets | 22,806 | 20,209 |
| Current assets: | Property and equipment, net | 39,497 | 40,474 |
| Current assets: | Goodwill | 66,152 | 66,152 |
| Current assets: | Other, net | 7,697 | 8,043 |
| Current assets: | Total assets | 136,152 | 134,878 |
| Current liabilities: | Current portion of notes payable, net of unamortized debt issuance costs | 4,016 | 4,014 |
| Current liabilities: | Accounts payable and accrued expenses | 4,990 | 4,066 |
| Current liabilities: | Accrued wages and bonuses | 5,355 | 7,218 |
| Current liabilities: | Deferred revenue | 16,716 | 16,201 |
| Current liabilities: | Dividends payable | 3,542 | 3,625 |
| Current liabilities: | Other current liabilities | 400 | 1,496 |
| Current liabilities: | Total current liabilities | 35,019 | 36,620 |
| Current liabilities: | Notes payable, net of current portion and unamortized debt issuance costs | 86,012 | 75,021 |
| Current liabilities: | Other non-current liabilities | 8,572 | 9,247 |
| Current liabilities: | Total liabilities | 129,603 | 120,888 |
| Shareholders’ equity: | Common stock, $0.001 par value; authorized 110,000,000 shares, issued 31,975,649 in 2026 and 31,966,504 in 2025, outstanding 22,139,315 in 2026 and 22,637,252 in 2025 | 32 | 32 |
| Shareholders’ equity: | Additional paid-in capital | 192,998 | 183,880 |
| Shareholders’ equity: | Retained earnings (accumulated deficit) | -24,507 | -17,298 |
| Shareholders’ equity: | Treasury stock | -161,974 | -152,624 |
| Shareholders’ equity: | Total shareholders’ equity | 6,549 | 13,990 |
| Shareholders’ equity: | Total liabilities and shareholders’ equity | 136,152 | 134,878 |
Cash Flow
Three months ended June 30, — (In thousands, unaudited) (in thousands)
| Three months ended June 30, – 2026 | Three months ended June 30, – 2025 | Six months ended June 30, – 2026 | Six months ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Cash flows from operating activities: | Net income | -3,283 | -106 | -61 | 5,681 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Depreciation and amortization | 2,121 | 1,742 | 4,290 | 3,284 |
Cash Flow
Three months ended June 30, — Free Cash Flow and Free Cash Flow Margin
| Three months ended June 30, – 2026 | Three months ended June 30, – 2025 | Six months ended June 30, – 2026 | Six months ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Net cash provided by (used in) operating activities | 1,386 | -1,139 | 8,566 | 5,507 | |
| Less: | Capital expenditures | 1,324 | 3,010 | 3,158 | 5,996 |
| Less: | Free cash flow | 62 | -4,149 | 5,408 | -489 |
| Less: | Net cash provided by operating activities margin | 4.0% | -3.0% | 12.0% | 8.0% |
| Less: | Free cash flow margin | -12.0% | 8.0% | -1.0% |
Full release
Forward-Looking Statements
This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements may be identified by their use of terms or phrases such as “believes,” “expect,” “focus,” “potential,” “will,” derivations thereof, and similar terms and phrases. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements, including those risks and uncertainties as set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2025, and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.
Media Contact marketing@nrchealth.com
Investor Contact ir@nrchealth.com
© NRC Health
NRC Health Announces First Quarter 2026 Results
Page 4
July 28, 2026
NRC HEALTH
Condensed Consolidated Statements of Income
(In thousands except per share data, unaudited)
© NRC Health
NRC Health Announces First Quarter 2026 Results
Page 5
July 28, 2026
NRC HEALTH
Condensed Consolidated Balance Sheets
(Dollars in thousands except share amounts and par value)
© NRC Health
NRC Health Announces First Quarter 2026 Results
Page 6
July 28, 2026
NRC HEALTH
Condensed Consolidated Statements of Cash Flows
(In thousands, unaudited)
© NRC Health
NRC Health Announces First Quarter 2026 Results
Page 7
July 28, 2026
NRC HEALTH
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands, except per share data, unaudited)
Adjusted Net Income and Adjusted Earnings per Share
© NRC Health
NRC Health Announces First Quarter 2026 Results
Page 8
July 28, 2026
Adjusted EBITDA and Adjusted EBITDA Margin
Free Cash Flow and Free Cash Flow Margin
© NRC Health